Introduction
Gamma knife radiosurgery (GKS) has been successfully used in the treatment of mesial temporal lobe epilepsy (MTLE) and epileptic seizures caused by difficult-to-access lesions, including intracerebral tumors, arteriovenous malformations, cavernous hemangioma, and hypothalamic harmatomas. [1] [2] [3] [4] [5] [6] [7] [8] In a multi-center European study enrolling 21 patients with MTLE indicated for temporal lobectomy, 13 patients were seizure-free for 2 years after GKS treatment. 1 In addition, there was no neuropsychological deterioration in these patients. 1 The results were encouraging and were comparable to those achieved by conventional standard anterior temporal lobectomy (ATL) or selective amygdalo-hippocampectomy. 9 After >5 years of follow-up, 9 out of 16 patients remained seizure-free. 7 Disadvantages of GKS for the treatment of MTLE, nonetheless, included acute or chronic post-irradiation side effects due to a large target volume; also, significant seizure reduction was usually delayed, e.g., 9-12 months after GKS. 1, 7 Regarding irradiation dose, a marginal dose at 24 AE 1 Gy appeared much more effective than using a low dose (15-24 Gy), as reported in previous studies. 1, 7, [10] [11] [12] [13] In this prospective study, we enrolled patients with recurrent habitual complex partial seizures after incomplete ATL. Instead of reoperation, GKS was performed targeting solely the residual amygdalar and hippocampal tissues in each of the patients. To our knowledge, this target approach has not been reported previously.
Materials and methods
The database consisted of 324 patients who underwent standard ATL for the treatment of medically intractable MTLE; these patients were followed up at Taipei Veterans General Hospital between January 1, 1990 and December 31, 2004. Eligible To evaluate the efficacy and safety of gamma knife radiosurgery (GKS) in treating temporal lobe epilepsy, GKS was performed in four adult patients with recurrent complex partial seizures who underwent incomplete anterior temporal lobectomy (ATL) but were reluctant to undergo a second resective surgery. A marginal dose of 24.5-25 Gy, corresponding to 65-70% isodose curve, was delivered to the treatment target that included the residual amygdala and the head and anterior body of the hippocampus.
None of the patients had severe acute side effects but three patients had radiation-induced MRI signal changes around the target volume 13, 20, and 24 months after GKS, respectively. All four patients had significant seizure reduction during the first 6-month period and clinical efficacy persisted throughout the 2-year follow-up period. All of the patients also had improved neuropsychological profiles, including memory function and quality-of-life, compared to their pre-GKS conditions.
In conclusion, the safety and clinical efficacy of GKS make it a reasonable and suitable therapeutic alternative for patients with recurrent seizures after incomplete ATL. A higher marginal dose of >25 Gy and wider coverage may be more clinically beneficial but warrant further investigation.
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patients had recurrent complex partial seizures with or without secondary generalization, residual mesial temporal structures in MRI, no new postoperative EEG focus, and reluctance to undergo reoperation (further resective surgery). Using a Leksell gamma knife, standard radiosurgical lesioning was performed on the target volume. In this study, the target volume was determined and delineated in cooperation with neurosurgeon and neuroradiologist, and included residual amygdala and the head and anterior body of the hippocampus. The marginal dose was set at approximately 25 Gy. In addition, careful protection of surrounding critical structures was ensured to keep radiation doses to the optic apparatus and to brainstem below 12 Gy and 15 Gy, respectively.
All patients were discharged with pre-existing antiepileptic drugs (AEDs) after GKS and were then followed at the outpatient seizure clinic. In the event of initial worsening of seizures, the neurologist in charge could increase the dose of pre-existing AEDs, using short-term treatment with a benzodiazepam like clobazam or midzolam, or add another AED in cases of cluster seizures or status epilepticus. Seizure frequency and adverse events were recorded in a seizure diary issued by Taiwan Epilepsy Society. In this study, we included in the analysis only complex partial seizures with or without secondary generalization and excluded ''auras'' or simple partial seizures.
Serial MRIs were conducted in all patients for the detection of any remarkable radiation-induced signal changes on target. Neuropsychological assessments including memory function (Weschler Memory Scale-III, face and word list subtests), intelligent quotient (IQ), and quality-of-life questionnaire were performed prior to and 2 years after GKS.
This study was approved by the Institutional Review Board and Ethics Committee of Taipei Veterans General Hospital. All patients gave consent forms.
Results
Clinical data from the four patients who received GKS treatment are shown in Table 1 . All four patients were females, 24-39 years of age and 3-15 years after ATL; two were previously operated on the right side and two on the left side. We have excluded three other patients; one who responded dramatically to a new AED add-on and two who insisted on AED treatment only. MRI (Fig. 1A ) demonstrated residual mesial temporal structures including the amygdala, the head and anterior body of the hippocampus, and parahippocampal gyrus in one of the patients (#1).
The marginal dose of GKS was 24.5-25 Gy in the patients in this study, corresponding to the 65-70% isodose curve; the mean dose ranged from 30 Gy to 31.2 Gy. The target volume was 2.4-3.8 ml, with 96-99% coverage of lesions, including residual amygdala and the head and anterior body of the hippocampus (Fig. 2) .
All patients were discharged on the day following GKS. At the first 2-week outpatient visit, no patients reported severe acute side effects, which would indicate increased intracranial pressure (IICP). During the initial visits throughout the first 6 months, there was no initial worsening of seizures, and no status epilepticus occurred in any of the patients during the 2-year follow-up period. Routine blood cell count and serum biochemistry follow-ups were within the normal range in all patients.
With respect to seizure control, significant seizure reduction was found following the first 6-month period after GKS (Table 1 ). Though none of the patients became seizure-free, a 28.0-66.7% seizure reduction rate compared with that before GKS was achieved during the final 6-month period of the 2-year follow-up. Based on the average number of seizures per month, three patients (#1, #3, and #4) experienced >50% seizure reduction throughout the 2-year follow-up period. Seizure reduction did not correlate well with the occurrence of radiation-induced signal changes in the MRI; these changes occurred 13, 20, and 24 months after GKS, respectively, in three patients (Fig. 1B) . All three of these patients tolerated the MRI signal changes and/or swelling well, and none required corticosteroid treatment. One patient (#2) underwent reoperation to remove residual mesial temporal structures after the 2-year follow-up period.
The Weschler Memory Scale follow-up at 2-year post-GKS showed improved scores compared to those achieved before GKS in all the patents. Three patients improved >6 points in the nonverbal face recognition subtest and three patients improved significantly in verbal word list recall and recognition subtests ( Table 1 ). In IQ follow-up, one patient had >9 points increase in full IQ and three patients were stable. On quality-of-life questionnaires, all patients had better scores after GKS.
Discussion
In this study reporting results with four patients, GKS appears to be effective in the treatment of recurrent seizures after incomplete ATL. By comparison, reoperations were performed among <4.7% of patients after temporal lobe resection for the treatment of epilepsy in Montreal Neurological Institute.
14 Though seizure-free or ''having rare seizures'' outcomes were achieved in 45-63% of patients after reoperation, the risk of surgical morbidity and cost for re-evaluation must be considered. 14, 15 Finally, GKS does not exclude future reoperation; one of our patients and one patient of Bartolomei et al. 7 underwent reoperation with favorable seizure control after unsatisfactory GKS.
In comparison with earlier reports, 1, 7 we found no initial worsening of seizures in any of the patients after GKS. In addition, after the earlier follow-up periods, a notable seizure reduction was found that persisted throughout the 2-year period, though none of the patients became seizure-free. In contrast to previous studies, only complex partial seizures were included in the analysis of recurrences in the present study. Our rationale for this is that impairment of consciousness is quite disabling for the patients and can lead to unexpected injury or mortality, whereas the auras or simple partial seizures which patients experienced were either variable or non-specific and could usually be tolerated. Other clinical benefits of GKS identified in this study include improved neuropsychological profiles, including memory function and quality-of-life. In this study, seizure control in patients was not as promising as that suggested by previous studies in MTLE patients who had not received prior surgical treatment. 1, 7 We proposed the following hypothesis to explain the result. First, a marginal dose of 24.5-25 Gy at 65-70% isodose curve, i.e., a maximal isocenter dose at 35.7-38.5 Gy, or a mean dose at 30-31.2 Gy, may be inadequate. The low marginal dose may also be reflected in the observed delayed occurrence of radiation-induced MRI signal changes in our patients, 13-24 months vs. the more usual 9-12 months after GKS. 1, 7 In addition, none of our patients experienced severe acute post-irradiation side effects after GKS or developed apparent IICP symptoms such as headache, while radiationinduced MRI signal changes, which required corticosteroid treatment, occurred in approximately 60% of patients in the previous studies. 1, 7 Second, our coverage of lesions mimicking a GKS-induced selective amygdalo-hippocampectomy may be too limited. Indeed, while delineating the target volume, the possibility of using a wider coverage including the entire residual mesial temporal structures and the parahippocampal gyrus was considered. However, due to a concern as to whether GKS might induce a severe cerebral edema in patients who had undergone ATL and in order to maximize protection of nearby brainstem and optic tracts, we chose a restrictive but seemingly safe target volume. The third possible reason for the somewhat lower effectiveness of GKS observed in the present study compared to other studies relates to postoperative changes. One hypothesis of how focal irradiation acts to reduce seizures is that, since neurons are more radio-resistant than supporting structures, neuronal damage in the epileptogenic focus is caused by ischemia due to vascular inflammation. 8 In our patients, advanced scar formation in the treated areas and subsequent shrinkage of vasculature due to previous ATL might have negatively affected neuronal response to GKS. Fourth, in any of our patients, the epileptogenic focus might have been located outside of the mesial temporal structures. This concern seems less compelling, since all patients had congruent data indicating MTLE during presurgical evaluation, which included continuous video-EEG monitoring, MRI and positron emission tomography. In addition, none of the patients developed new EEG foci after ATL.
In conclusion, the safety and clinical efficacy of GKS demonstrated in this study show that GKS is a reasonable and suitable therapeutic alternative for patients with recurrent seizures after incomplete ATL who are psychologically or physically not indicated for reoperation. The optimal GKS technical parameters for these patients, including target dose and volume, deserve further study. 
